AstraZeneca Pharma India

Sebi said that the entire procedure was intended to dilute the reverse book building mechanism for discovery of delisting price of the scrip as per stipulations

British drugmaker AstraZeneca, which has committed to invest $90 million in India over five years, has set up Integrated Cardio Metabolic Centre in Kerala for holistic treatment of diabetes

The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.